While targeting Bcl-2 can be effective, there are limitations. Cancer cells may develop resistance to Bcl-2 inhibitors through various mechanisms, such as upregulation of other anti-apoptotic proteins or mutations in apoptotic pathways. Therefore, combination therapies are often required to achieve better clinical outcomes.
